Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | CASP6 | P55212 | 2/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10898569 | 0.88 | KAT8 (0.48) | ALDH1A1TP53MRGPRX4TDP1POLB | |
| SCHEMBL22032180 | 0.87 | TSHR (0.50) | ALDH1A1TP53TDP1LCKRECQL | |
| SCHEMBL8389875 | 0.84 | LCK (0.47) | ALDH1A1TDP1POLBLCKMEN1 | |
| SCHEMBL664212 | 0.81 | ALDH1A1 (0.55) | ALDH1A1TP53MRGPRX4TDP1POLB | |
| SCHEMBL11445345 | 0.79 | TAAR1 (0.58) | ALDH1A1TP53MRGPRX4TDP1POLB | |
| SCHEMBL27885967 | 0.79 | ALDH1A1 (0.53) | ALDH1A1TP53MRGPRX4TDP1POLB | |
| SCHEMBL15808849 | 0.79 | MEN1 (0.57) | ALDH1A1TP53MRGPRX4TDP1POLB | |
| SCHEMBL27902483 | 0.79 | ALDH1A1 (0.53) | ALDH1A1TP53MRGPRX4TDP1POLB | |
| SCHEMBL1150953 | 0.78 | PNMT (0.55) | ALDH1A1TP53MAPTMEN1KMT2A | |
| SCHEMBL11485420 | 0.78 | TSHR (0.47) | ALDH1A1TDP1LCKNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| US-20080139636-A1 | Adamantane derivatives | ASTRAZENECA AB. | 2008-06-12 | — | — | US | disclosed |
| EP-1862451-A1 | Adamantane derivatives for the treatment of inflammatory diseases | AstraZeneca AB (SE) | 2007-12-05 | — | — | EP | disclosed |
| US-7297818-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2007-11-20 | — | — | US | disclosed |
| CN-1312120-C | Adamantane derivatives | ASTRAZENECA AB (SE) | 2007-04-25 | — | — | CN | disclosed |
| US-20070082957-A1 | Adamantane derivatives | ASTRAZENECA AB | 2007-04-12 | — | — | US | disclosed |
| US-7132457-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-6881754-B2 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2005-04-19 | — | — | US | disclosed |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | ASTRAZENECA AB | 2005-03-03 | — | — | US | disclosed |
| EP-1242364-B1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-03-17 | — | — | EP | disclosed |
| EP-1352896-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352897-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| EP-1352895-A2 | Adamantane derivatives for the treatment of inflammatory, immune and cardiovascular diseases | AstraZeneca AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| CN-1434794-A | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-08-06 | — | — | CN | disclosed |
| US-20030013704-A1 | Adamantane derivatives | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | US | disclosed |
| EP-1242364-A1 | ADAMANTANE DERIVATIVES | AstraZeneca AB (SE) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001044170-A1 | ADAMANTANE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082957-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | ALDH1A1 282/4885TP53 3572/4885MRGPRX4 2523/4885 |
| US-20030013704-A1 | Adamantane derivatives | ADRA2C, CHRNA2, ADRA1D | ALDH1A1 398/4885TP53 4159/4885MRGPRX4 2622/4885 |
| US-20090176853-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | ALDH1A1 328/4885TP53 3528/4885MRGPRX4 2407/4885 |
| US-20050049303-A1 | 2-Chloro-5-[3-[(2-hydroxyethyl)amino]propyl]-N-(tricyclo[3.3.1.13,7]dec-1-ylmethyl)-benzamide; preparation from chemical intermediates; use in treating rheumatoid arthritis, chronic obstructive pulmonary disease | HRH1, HRH2, HRH4 | ALDH1A1 126/4885TP53 3751/4885MRGPRX4 2308/4885 |
| US-20080139636-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | ALDH1A1 328/4885TP53 3528/4885MRGPRX4 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.